Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
A prospective collection of data on the treatment of Chinese patients with relapsed/refractory follicular lymphoma (FL) using Axicabtagene Ciloleucel Injection, and evaluation of the efficacy and safety of Axicabtagene Ciloleucel Injection in this treatment.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University